Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stereotaxis anticipates revenue growth in 2023 with key innovations

Stereotaxis is poised for growth with key innovations nearing commercialization and a strong balance sheet.
Strategic collaborations, improved pipeline visibility, and targeted growth strategies position the company for future success.
Challenges in customer engagement and market penetration require proactive strategies to drive revenue growth.
Opportunities in SaaS business spin-off, IDN engagement, and product launches offer avenues for revenue expansion and market presence.

Stereotaxis Inc reports revenue decline but expects growth opportunities

Stereotaxis Inc reports revenue decline but expects growth with Genesis
Positive feedback on technology, regulatory progress, and innovation efforts
Challenges include catheter shortages and financial balancing act
Opportunities lie in increasing system orders and upcoming market releases

Stereotaxis Inc reports robust revenue growth and strategic collaborations

Stereotaxis Inc's Q2 2023 performance showcased strong revenue growth and strategic collaborations driving innovation.
While facing challenges like regulatory delays and cash flow issues, the company is focused on reducing cash usage and advancing key projects.
Opportunities lie in connectivity software releases, product development, and regulatory submissions, positioning Stereotaxis for future growth.

Stereotaxis reports Q3 revenue growth, faces operational challenges

Stereotaxis Inc saw modest revenue growth in Q3 driven by robotic system sales, but faced an operating loss.
Maintaining a strong financial position with no debt provides stability amidst operational challenges.
The company's focus on innovation and market strategies presents opportunities for future growth and product development.

Stereotaxis Inc reports Q4 revenue of $4.6M, focuses on innovation and regulatory progress

Stereotaxis Inc navigated challenges in Q4 2023 with a focus on innovation and strategic transformation. Strong financial position and confidence in regulatory processes position the company well for future growth. Revenue guidance for 2024 indicates potential for stable recurring revenue and increased system revenue.

Stereotaxis reports Q1 revenue growth, innovation progress, and APT acquisition

Stereotaxis Inc's Q1 2024 earnings call highlighted revenue growth, innovation progress, and the acquisition of APT. Despite challenges with recurring revenue and an operating loss, the company is optimistic about future growth driven by system backlog and new orders.

Stereotaxis Inc. reports Q2 loss, anticipates growth from GenesisX shipments

Stereotaxis Inc. faces challenges from reduced capital revenue but shows resilience with stable recurring revenue and a strong gross margin.
The company's strategic initiatives, including GenesisX and the APT acquisition, position it well for future growth and market expansion.
Analysts' inquiries reflect interest in key growth drivers like GenesisX, manufacturing scale-up, and macroeconomic influences on the business.
Overall, Stereotaxis Inc. aims for a stronger second half in 2024, leveraging new product offerings and revenue streams for improved financial performance.

Stereotaxis Inc reports revenue growth in Q3 2024 earnings

Stereotaxis Inc showed solid revenue growth in Q3 2024, driven by system and recurring revenue.
While facing challenges in operating expenses and profitability, the company has opportunities for growth.
Managing expenses and capitalizing on revenue potential could position Stereotaxis for improved financial performance.
The increase in cash reserves also provides a buffer for future investments and operations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - TD Cowen Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis Third Quarter 2024 Earnings Conference Call.

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.

Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024.

Stereotaxis Reports 2024 Third Quarter Financial Results

ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal.

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will represent Stereotaxis at two upcoming investor conferences.

Stereotaxis to Present at Upcoming Investor Conferences

ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

GenesisX was approved in Europe and is set to be approved in the US late this year. The new robot is a giant leap forward in accessibility. Stereotaxis should get MAGiC approved in Europe in October. I expect a US approval no later than Q2 2025. The firm has enough cash to reach breakeven. It won't hire a lot of people right away to sell GenesisX.

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.

Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX

Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.

Stereotaxis (STXS) Receives European Approval for GenesisX

Stereotaxis, Inc. (NYSE:STXS ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Adam Maeder - Piper Sandler Josh Jennings - TD Cowen Nelson Cox - Lake Street Capital Markets Operator Good afternoon, and welcome to the Stereotaxis, Inc. Second Quarter 2024 Earnings Conference Call. Certain statements during the call and question-and-answer period to follow may relate to future events, expectations and, as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago.

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024.

Stereotaxis Reports 2024 Second Quarter Financial Results

Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been submitted to the FDA for 510(k) clearance in the United States ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE mark in Europe and submitted a 510(k) application to the FDA in the US for a next generation robotic system, GenesisX.

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 second quarter on Monday, August 12, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi” Shamir to its Board of Directors.

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, renowned for advanced clinical research, innovation, and compassionate patient care, stands at the forefront as the first in the Northeast United States to offer the Genesis System.

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.

Stereotaxis (STXS) Gets CE Recertification for Approved Products

Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.

Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias

ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. The recertification under MDR covers all Stereotaxis devices currently available in Europe.

Stereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory Framework

Stereotaxis made a strategic acquisition of catheter company Access Point Technologies, which is expected to contribute $5 million in sales in the first 12 months after the acquisition. Access Point will help Stereotaxis release a robotically navigated guide catheter and a robotically navigated mapping catheter. Stereotaxis is working with regulators to get MAGiC approved. The CE Mark should be coming late this summer. PMA approval should come at year-end.

Stereotaxis Makes A Strategic Acquisition Bolstering Its Future

Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.

First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology

Stereotaxis presents innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablati

Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa

Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.

Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies

Stereotaxis, Inc. (NYSE:STXS ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH MKM Adam Maeder - Piper Sandler Joshua Jennings - TD Cowen Operator Good afternoon. Thank you for joining us for Stereotaxis' First Quarter 2024 Earnings Conference Call.

News for Stereotaxis Inc Stock (STXS)